Glorieux FH - Search Results

1

Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta.

Munns CF, Rauch F, Mier RJ, Glorieux FH. Munns CF, et al. Among authors: glorieux fh. Bone. 2004 Jul;35(1):231-4. doi: 10.1016/j.bone.2004.03.008. Bone. 2004. PMID: 15207762

2

Assessment of longitudinal bone growth in osteogenesis imperfecta using metacarpophalangeal pattern profiles.

Rauch D, Robinson ME, Seiltgens C, Sutton VR, Lee B, Glorieux F, Rauch F. Rauch D, et al. Bone. 2020 Nov;140:115547. doi: 10.1016/j.bone.2020.115547. Epub 2020 Jul 27. Bone. 2020. PMID: 32730936 Free PMC article.

3

Osteogenesis imperfecta tooth level phenotype analysis: Cross-sectional study.

Taqi D, Moussa H, Schwinghamer T, Ducret M, Dagdeviren D, Retrouvey JM, Rauch F, Tamimi F; Members of the BBDC. Taqi D, et al. Bone. 2021 Jun;147:115917. doi: 10.1016/j.bone.2021.115917. Epub 2021 Mar 16. Bone. 2021. PMID: 33741542 Free PMC article.

4

Craniofacial and dental phenotype of two girls with osteogenesis imperfecta due to mutations in CRTAP.

Marulanda J, Ludwig K, Glorieux F, Lee B, Sutton VR; Members of the BBD Consortium; Retrouvey JM, Rauch F. Marulanda J, et al. Bone. 2022 Nov;164:116516. doi: 10.1016/j.bone.2022.116516. Epub 2022 Aug 12. Bone. 2022. PMID: 35970273 Free PMC article.

5

Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Glorieux FH, et al. J Bone Miner Res. 2002 Jan;17(1):30-8. doi: 10.1359/jbmr.2002.17.1.30. J Bone Miner Res. 2002. PMID: 11771667 Free article.

6

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.

Rauch F, Travers R, Plotkin H, Glorieux FH. Rauch F, et al. Among authors: glorieux fh. J Clin Invest. 2002 Nov;110(9):1293-9. doi: 10.1172/JCI15952. J Clin Invest. 2002. PMID: 12417568 Free PMC article.

7

Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.

Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Rauch F, et al. Among authors: glorieux fh. J Clin Endocrinol Metab. 2003 Mar;88(3):986-92. doi: 10.1210/jc.2002-021371. J Clin Endocrinol Metab. 2003. PMID: 12629073

8

Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.

Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Rauch F, et al. Among authors: glorieux fh. J Bone Miner Res. 2003 Apr;18(4):610-4. doi: 10.1359/jbmr.2003.18.4.610. J Bone Miner Res. 2003. PMID: 12674321 Free article.

9

Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.

Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Zeitlin L, et al. Among authors: glorieux fh. Pediatrics. 2003 May;111(5 Pt 1):1030-6. doi: 10.1542/peds.111.5.1030. Pediatrics. 2003. PMID: 12728084

10

Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta.

Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, Glorieux FH. Montpetit K, et al. Among authors: glorieux fh. Pediatrics. 2003 May;111(5 Pt 1):e601-3. doi: 10.1542/peds.111.5.e601. Pediatrics. 2003. PMID: 12728117

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

336 results

Search Page

Filters